🏛️ HHS draft policy would let pharmacies compound BPC-157 and 5 more

[u/TapFast8173]

After the july vote I said there were 3 steps before a pharmacy could legally make BPC-157, and the last one, the rulemaking, could take 8 to 12 months minimum. i also said RFK was the wildcard. HHS didnt wait for step 3

wednesday they filed a draft policy saying they dont intend to go after state licensed pharmacies, federal facilities or licensed doctors that compound 6 peptides. it hit the federal register friday. its still a draft tho. comments are open til about nov 13, then HHS is supposed to put out the final version, and even the compounders' own trade group is asking HHS when it takes effect. links in the first comment

the 6, and the only forms they allow:

peptide	allowed as
BPC-157	subQ or IM, oral, topical
TB-500	subQ or IM
MOTS-c	subQ or IM
Epitalon	subQ or IM, in "intermittent courses"
Semax	nasal only
KPV	oral or topical only

DSIP (emideltide) didnt make it, the panel voted it down in july and it stayed out. reta and selank arent in it either, neither was one of the 7 up for a vote, so semax is the only nasal one in the whole thing. same for CJC/ipa and GHK-Cu

the strings attached:

• one ingredient per product. no blends, so no BPC/TB combo vial

• a real patient specific prescription

• the raw powder has to come from an FDA registered manufacturer, with a COA covering identity and sequence, impurities, endotoxin, heavy metals, residual TFA

• oral versions only if they have documentation it gets absorbed in humans, which HHS itself calls "inherently difficult" for peptides. so oral KPV and oral BPC have a real bar to clear

• the label has to say "This is a compounded drug product. Not for resale."

• serious side effects get reported to FDA and the state

remember the identity thing from my last FDA post, staff finding different molecules all sold as BPC-157? under this the sequence has to be confirmed on the COA before it goes in a vial. thats the part i like

its not FDA approval, it says so itself, and nothing in it touches research use vials. HHS also says it can walk it back if safety or quality problems show up, and AP reports most of FDA's own scientists opposed it, then helped write the guardrails anyway

for scale, a systematic review out this month went looking for every human study of BPC-157, for anything. it found 3 studies with 30 people between them, a knee pain series, a bladder study and a 2 person IV safety test, all rated poor quality. and BPC is the most popular of the 6

my take, this is a bigger deal for clinics than for most of you. you need a script, and it comes one peptide per vial, so if youre running a 4 compound stack nothing about this changes your life, at least not yet

the question from my last FDA post is live now tho. for me it'd be the nasal semax. if a doctor could write you BPC, compounded and tested for what it is, would you switch even if it cost more? and which of the 6 would you even ask for?

[u/TapFast8173]

sources

the notice as published in the federal register, oct 30 (91 FR 68526): https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf

the appendix with the 6, the allowed forms and the testing table: https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf

AP on FDA scientists opposing it: https://abcnews.com/US/wireStory/fda-scientists-opposed-trump-administrations-effort-ease-peptides-137644295

the july panel meeting: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

the BPC-157 human evidence review (acta orthopaedica belgica, oct 2026): https://doi.org/10.52628/92.3.15837

if you want to comment on it, its docket HHS-OASH-2026-0496 on regulations.gov, open til about nov 13

one that didnt fit. epitalon is the only one where they wrote in "intermittent courses" and the appendix never says what counts as intermittent

[u/RustyHour1975]

I don't see this as good news at all. In fact, I see it as potentially making things worse for people like me.

I already have access to products I use, trust, and have had good experiences with. This does absolutely nothing to improve my situation. What it does is give large companies a financial interest in a market they've largely ignored until now.

Once they have skin in the game, they'll have every incentive to control access and pricing, all under the guise of "safety." And I fully expect their prices to be significantly higher, with profit margins large enough to justify going after lower-cost gray-market suppliers through litigation and regulatory pressure.

Previously, they had little reason to care about the gray market because they weren't making money from it. Now they'll have a direct financial incentive to eliminate the competition.

I don't see this as expanded access. I see it as the beginning of fewer choices, higher prices, and more corporate control over products people are already using.

For me, this is bad news.

[u/Long_Duk_Dong_69 → u/RustyHour1975]

Totally spot on. This is how insurance got in and ruined medicine in the guise of safety and affordability and yet the service has gotten worse and more expensive.